Pneumocystis Jirovecii Infection
7
1
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
43%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
How Long Should we Give Steroids for Patients With Severe PCP
Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
Factors Associated With Survival in Patients Having Pneumocystis Jirovecii
Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients